02:37 , Jan 26, 2013 |  BC Extra  |  Financial News

BG raises $12 million in follow-on

Diagnostics company BG Medicine Inc. (NASDAQ:BGMD) raised $12 million through the sale of 6 million shares at $2 in a follow-on underwritten by Lazard. BG Medicine proposed the offering late Thursday, when its share price...
01:57 , Jan 25, 2013 |  BC Extra  |  Financial News

BG proposes follow-on

Diagnostics company BG Medicine Inc. (NASDAQ:BGMD) said it is planning a follow-on underwritten by Lazard. BG also said that Aspire Capital Fund agreed to purchase up to $12 million in BG Medicine stock over the...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

CardioSCORE regulatory update

BG Medicine said its CardioSCORE test received CE Mark approval to predict major cardiovascular events. The company said it expects to launch the in vitro diagnostic multivariate index (IVDMIA) assay that measures multiple protein biomarkers...
08:00 , Dec 17, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Actelion Ltd. (SIX:ATLN) was down CHF1.34 to CHF44.99 on Friday after announcing FDA accepted for review an NDA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). A decision is expected around October...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

BG Medicine diagnostic news

BG Medicine reduced headcount by 11 (30%) to 26 as part of its strategy to transition into a commercially focused company to support sales and marketing of its BGM Galectin-3 heart failure risk and CardioSCORE...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

CardioSCORE regulatory update

BG Medicine withdrew a 510(k) application to FDA for its CardioSCORE diagnostic to identify patients at high risk for near-term major cardiovascular events, including heart attack or stroke. BG Medicine made the decision after determining...
07:00 , Aug 13, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) fell $0.39 (14%) to $2.41 on Wednesday after the U.K.'s NICE issued draft guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant to treat chronic diabetic macular...
00:23 , Aug 10, 2012 |  BC Extra  |  Company News

BG Medicine withdraws 510(k) for CardioSCORE

BG Medicine Inc. (NASDAQ:BGMD) withdrew a 510(k) application to FDA for its CardioSCORE (formerly AMIPredict ) diagnostic to identify patients at high risk for near-term major cardiovascular events, including heart attack or stroke. BG Medicine...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

CardioSCORE: Pivotal trial data

Data from the U.S. pivotal BioImage Study in 6,600 subjects with no prior history of cardiovascular disease showed that testing with BG Medicine's CardioSCORE diagnostic at baseline significantly improved the identification of subjects at high...